Suppr超能文献

使用靶向Bcl-2和Bcl-xL基因的双特异性反义寡核苷酸诱导人前列腺癌LNCaP细胞凋亡并增强其化学敏感性。

Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.

作者信息

Yamanaka Kazuki, Rocchi Palma, Miyake Hideaki, Fazli Ladan, So Alan, Zangemeister-Wittke Uwe, Gleave Martin E

机构信息

The Prostate Centre, Vancouver General Hospital, Vancouver, Canada.

出版信息

BJU Int. 2006 Jun;97(6):1300-8. doi: 10.1111/j.1464-410X.2006.06147.x.

Abstract

OBJECTIVE

To determine whether a specifically designed bispecific (Bcl-2/Bcl-xL) antisense oligonucleotide (ASO) induces apoptosis and enhances chemosensitivity in human prostate cancer LNCaP cells, as Bcl-2 and Bcl-xL are both anti-apoptotic genes associated with treatment resistance and tumour progression in many malignancies, including prostate cancer.

MATERIALS AND METHODS

Inhibition of Bcl-2 and Bcl-xL expression by the bispecific ASO was evaluated using real-time reverse transcription-polymerase chain reaction and Western blotting, while growth inhibition and induction of apoptosis were analysed by a crystal violet assay, flow cytometry and Western blotting of apoptosis-relevant proteins. The effect of combined treatment with bispecific ASO and chemotherapy or small-interference RNA (siRNA) targeting the clusterin gene was also investigated.

RESULTS

Bispecific ASO reduced Bcl-2 and Bcl-xL expression in LNCaP cells in a dose-dependent manner. There was cell growth inhibition, increases in the sub-G0-G1 fraction, and cleavage of caspase-3 and poly(ADP-Ribose) polymerase proteins in LNCaP cells after bispecific ASO treatment. Interestingly, Bcl-2/Bcl-xL bispecific ASO treatment also resulted in the down-regulation of Mcl-1 and up-regulation of Bax. The sensitivity of LNCaP cells to mitoxantrone, docetaxel or paclitaxel was significantly increased, reducing the 50% inhibitory concentration by 45%, 80% or 90%, respectively. Furthermore, the apoptotic induction by Bcl-2/Bcl-xL bispecific ASO was synergistically enhanced by siRNA-mediated inhibition of clusterin, a cytoprotective chaperone that interacts with and inhibits activated Bax.

CONCLUSIONS

These findings support the concept of the targeted suppression of Bcl-2 anti-apoptotic family members using multitarget inhibition strategies for prostate cancer, through the effective induction of apoptosis.

摘要

目的

确定一种专门设计的双特异性(Bcl-2/Bcl-xL)反义寡核苷酸(ASO)是否能诱导人前列腺癌LNCaP细胞凋亡并增强其化学敏感性,因为Bcl-2和Bcl-xL都是抗凋亡基因,在包括前列腺癌在内的许多恶性肿瘤中与治疗抵抗和肿瘤进展相关。

材料与方法

使用实时逆转录-聚合酶链反应和蛋白质免疫印迹法评估双特异性ASO对Bcl-2和Bcl-xL表达的抑制作用,同时通过结晶紫测定法、流式细胞术和凋亡相关蛋白的蛋白质免疫印迹法分析生长抑制和凋亡诱导情况。还研究了双特异性ASO与化疗或靶向聚集素基因的小干扰RNA(siRNA)联合治疗的效果。

结果

双特异性ASO以剂量依赖性方式降低LNCaP细胞中Bcl-2和Bcl-xL的表达。双特异性ASO处理后,LNCaP细胞出现细胞生长抑制、亚G0-G1期分数增加以及半胱天冬酶-3和聚(ADP-核糖)聚合酶蛋白的裂解。有趣的是,Bcl-2/Bcl-xL双特异性ASO处理还导致Mcl-1下调和Bax上调。LNCaP细胞对米托蒽醌、多西他赛或紫杉醇的敏感性显著增加,分别将50%抑制浓度降低了45%、80%或90%。此外,siRNA介导的聚集素抑制协同增强了Bcl-2/Bcl-xL双特异性ASO的凋亡诱导作用,聚集素是一种细胞保护伴侣蛋白,可与活化的Bax相互作用并抑制其活性。

结论

这些发现支持了通过有效诱导凋亡,采用多靶点抑制策略靶向抑制前列腺癌中Bcl-2抗凋亡家族成员的概念。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验